New England Journal of Medicine publishes long-term results of Gleevec®

In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec®*, as an oral therapy for patients with chronic myeloid leukemia, or CML. The New England Journal of Medicine has published results from a nearly 11-year follow-up study, that showed an estimated overall survival rate of 83.3 percent. According to the National Cancer Institute, prior to Gleevec's 2001 FDA approval, fewer than 1 in 3 CML patients survived five years past diagnosis.

Brian Druker, M.D., who led the original clinical development of Gleevec, co-authored the study. The worldwide study enrolled 1,106 participants at 177 cancer centers in more than 16 countries.

"The long-term success of this treatment confirms the remarkable success we've seen since the very first Gleevec trials," said Druker, director of the OHSU Knight Cancer Institute, a Howard Hughes Medical Institute Investigator and JELD-WEN Chair of Leukemia Research in the OHSU School of Medicine. "This study reinforces the notion that we can create effective and non-toxic therapies."

The discovery of Gleevec ushered in the era of personalized cancer medicine, proving it was possible to shut down cells that enable cancer to grow without harming healthy ones.

In an accompanying editorial, "Imatinib Changed Everything," Dan Longo, M.D., professor of medicine, Harvard Medical School; and deputy editor, the New England Journal of Medicine, wrote: "The development of imatinib fundamentally altered the field of oncology. Priorities shifted from agents that were active on dividing cells to understanding the biology of individual types of cancer."

In addition to treating patients with CML, Gleevec has proved effective against multiple forms of cancer, including pediatric CML and gastrointestinal stromal tumor, or GIST. A recent study published in JAMA Oncology found that nearly 1 in 4 GIST patients treated with Gleevec will survive 10 years.

"Until Gleevec arrived on the scene 15 years ago, patients with advanced GISTs faced a life expectancy of 18 months," said Michael Heinrich, M.D., a professor of medicine (hematology and medical oncology) and cell and developmental biology in the OHSU School of Medicine; researcher with Portland Veterans Affairs Health Care System. "Now we've learned that some might live a decade or longer."

Druker says one advantage to treating CML patients with Gleevec is that most patients are diagnosed in a chronic stage of their illness: "Our results demonstrating Gleevec's high efficacy in CML tell us to realize the full promise of precision cancer medicine, we need to diagnose and treat patients earlier in the disease course."

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators.
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324.

Funding for the study was provided by Novartis Pharmaceuticals; IRIS ClinicalTrials.gov numbers NCT00006343 and NCT00333840; OHSU IRB number e1091.

* Gleevec is a trademark of Novartis Pharmaceuticals Corporation

Most Popular Now

Novartis drug Zykadia receives FDA Priority Review…

Novartis today announced that the US Food and Drug Administration (FDA) accepted the Company's supplemental New Drug Application (sNDA) for filing, and granted Priority R...

Read more

Mutual Recognition promises new framework for phar…

The United States and the European Union (EU) completed an exchange of letters to amend the Pharmaceutical Annex to the 1998 U.S.-EU Mutual Recognition Agreement. Under t...

Read more

New analysis shows Novartis Entresto improves glyc…

Novartis has announced results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes suggesting that Entr...

Read more

Drugs similar to aspirin, ibuprofen could help tre…

A potentially life-saving treatment for sepsis has been under our noses for decades in the non-steroidal anti-inflammatory drugs (NSAIDs) most people have in their medici...

Read more

Novartis' Cosentyx shows almost all psoriasis pati…

Novartis has announced a new analysis showing that moderate-to-severe psoriasis patients treated with Cosentyx® (secukinumab) rapidly regain clear or almost clear skin (P...

Read more

Scientists stimulate immune system, stop cancer gr…

Researchers at the University of Illinois at Chicago report that increasing expression of a chemical cytokine called LIGHT in mice with colon cancer activated the immune ...

Read more

Potential drug candidates halt prostate and breast…

Scientists on the Florida campus of The Scripps Research Institute (TSRI) have designed two new drug candidates to target prostate and triple negative breast cancers. The...

Read more

Johnson & Johnson completes acquisition of Abb…

Johnson & Johnson (NYSE: JNJ) has completed the acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott. The all-cash $4.325 billion acquisition w...

Read more

New England Journal of Medicine publishes long-ter…

In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec®*, as an oral therapy for patients with chronic m...

Read more

Bristol-Myers Squibb expands focus on precision me…

Bristol-Myers Squibb Company (NYSE: BMY) announced its equity investment and plans for a research collaboration with GRAIL Inc., a life sciences company whose mission is ...

Read more

Volkswagen's excess emissions will lead to 1,200 p…

In September 2015, the German Volkswagen Group, the world's largest car producer, admitted to having installed "defeat devices" in 11 million diesel cars sold worldwide b...

Read more

Another record year for Bayer - good progress with…

Bayer had a very successful year in 2016, both strategically and operationally. Sales of the Bayer Group increased in 2016 by 1.5 percent (Fx & portfolio adj. 3.5 percent...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]